Synergistic bacterial compositions and methods of production and use thereof
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
1. A composition comprising a first species of isolated bacterium and a second species of isolated bacterium and a capsule, which encapsulates the first species, the second species, or both the first and second species of isolated bacterium, wherein the first species is Lachnospiraceae_bacterium_ 5_1_57FAA and the second species is Clostridium disporicum , wherein the Lachnospiraceae_bacterium_ 5_1_57FAA FAA comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in SEQ ID NO: 979, and wherein the first species and the second species are capable of inhibiting Clostridium difficile ( C. difficile ) growth as measured by a CivSim assay.
2. The composition of claim 1 , which further comprises an enteric coating.
3. The composition of claim 1 , wherein the first species and the second species are capable of inhibiting C. difficile growth in the CivSim assay with a confidence interval of >99% (++++).
4. The composition of claim 1 , wherein the first species, the second species, or both are in the form of spores.
5. The composition of claim 1 , which is formulated for populating the gastrointestinal tract of the subject.
6. The composition of claim 1 , wherein the first species, the second species, or both are lyophilized.
7. A kit comprising in one or more containers the composition of claim 1 .
8. A pharmaceutical formulation comprising the composition of claim 1 .
9. The pharmaceutical formulation of claim 8 , further comprising an additional agent.
10. The pharmaceutical formulation of claim 9 , wherein the additional agent is selected from an anti-bacterial agent, anti-fungal agent, anti-viral agent, anti-parasitic agent, or combinations thereof.
11. The composition of claim 1 , wherein the Lachnospiraceae_bacterium_ 5_1_57FAA comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 979.
12. The composition of claim 1 , wherein the Lachnospiraceae_bacterium_ 5_1_57FAA comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 979.
13. The composition of claim 1 , wherein the Clostridium disporicum comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 518.
14. The composition of claim 1 , wherein the Clostridium disporicum comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 518.
15. The composition of claim 1 , wherein the Clostridium disporicum comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 518.
16. The pharmaceutical formulation of claim 8 , which further comprises a pharmaceutically acceptable excipient.
17. The pharmaceutical formulation of claim 8 , which is formulated for oral administration.
18. The composition of claim 1 , which further comprises glycerol.
19. The composition of claim 1 , wherein the Lachnospiraceae_bacterium_ 5_1_57FAA comprises the 16S rDNA sequence set forth in SEQ ID NO: 979.
20. The composition of claim 1 , wherein the Clostridium disporicum comprises the 16S rDNA sequence set forth in SEQ ID NO: 518.